Key result
Broad use of statins, angiotensin receptor blockers, and selective serotonin reuptake inhibitors may partly explain the lack of impressive results with novel antiplatelet therapies due to their inherent platelet-inhibiting properties.
Non-conventional agents like statins, ARBs, and SSRIs have intrinsic antiplatelet effects that may confound the efficacy of traditional antiplatelet therapies in clinical trials.
No takes yet. Share an insight, caveat, or question.
Concomitant statins, ARBs, and SSRIs may confound novel antiplatelet trial results; leaves open whether adjusted analyses would alter efficacy estimates.
Malinin et al. (2006) conducted a review in Vascular events. Angiotensin receptor blockers, statins, and selective serotonin reuptake inhibitors was evaluated. Broad use of statins, angiotensin receptor blockers, and selective serotonin reuptake inhibitors may partly explain the lack of impressive results with novel antiplatelet therapies due to their inherent platelet-inhibiting properties.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: